{'fraction_non_alphanumeric': 0.01810344827586207, 'fraction_numerical': 0.011206896551724138, 'mean_word_length': 4.984536082474227, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pituitary ablation in diabetics with severe retinopathy.

. Pituitary ablation has been performed in 20 patients with diabetic retinopathy, including 18 with proliferative retinopathy. One postoperative death occurred. The remaining 19 patients have been observed for periods ranging from 22 to 131 months. Pituitary ablation had a distinct effect on the background retinopathy: the haemorrhages and red dots decreased in number, the phlebopathy improved, and newly formed vessels in the retina and iris disappeared in a few cases. However, the effects of operation seem to be of a transitory nature. After some years recurrence in the form of background or proliferative retinopathy and/or rubeosis of the iris was observed in some of the patients. The average decrease in vision was 11% in the group as a whole, but only two patients were blind in both eyes at the last follow-up examination. Pituitary ablation seems to have inhibited the development of both retinopathy and iridic changes, but only long-term observations in controlled clinical trials can decide whether this operation is to have a permanent place in the treatment of diabetic retinopathy.